Cyclin-Dependent Kinase Inhibitors in the Rare Subtypes of Melanoma Therapy

被引:1
|
作者
Kaszubski, Jonatan [1 ]
Gagat, Maciej [2 ,3 ]
Grzanka, Alina [2 ]
Wawrzyniak, Agata [4 ]
Niklinska, Wieslawa [5 ]
Lapot, Magdalena [3 ]
Zuryn, Agnieszka [2 ]
机构
[1] Nicolaus Copernicus Univ Torun, Fac Med, Dept Histol & Embryol, Coll Medicum Bydgoszcz,Vasc Biol Student Res Club, PL-85067 Bydgoszcz, Poland
[2] Nicolaus Copernicus Univ Torun, Fac Med, Dept Histol & Embryol, Coll Med Bydgoszcz, PL-85067 Bydgoszcz, Poland
[3] Mazovian Acad Plock, Fac Med, Coll Med, PL-09402 Plock, Poland
[4] Univ Rzeszow, Inst Med Sci, Coll Med Sci, Dept Histol & Embryol, PL-35310 Rzeszow, Poland
[5] Med Univ Bialystok, Dept Histol & Embryol, PL-15269 Bialystok, Poland
来源
MOLECULES | 2024年 / 29卷 / 22期
关键词
melanoma; rare subtypes of melanoma; mucosal melanoma; uveal melanoma; acral melanoma; cyclin-dependent kinases (CDKs); CDK inhibitors (CDKIs); CDK4/6; CDK7/9; CDK2; ACRAL MELANOMA; UVEAL MELANOMA; DESMOPLASTIC MELANOMA; GENETIC ABERRATIONS; P16; EXPRESSION; MAPK PATHWAY; DISTINCT; CANCER; COMBINATION; PROTEINS;
D O I
10.3390/molecules29225239
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Melanoma occurs in various forms and body areas, not only in the cutis, but also in mucous membranes and the uvea. Rarer subtypes of that cancer differ in genomic aberrations, which cause their minor sensibility to regular cutaneous melanoma therapies. Therefore, it is essential to discover new strategies for treating rare forms of melanoma. In recent years, interest in applying CDK inhibitors (CDKIs) in cancer therapy has grown, as they are able to arrest the cell cycle and inhibit cell proliferation. Current studies highlight selective CDK4/6 inhibitors, like palbociclib or abemaciclib, as a very promising therapeutic option, since they were accepted by the FDA for advanced breast cancer treatment. However, cells of every subtype of melanoma do not react to CDKIs the same way, which is partly because of the genetic differences between them. Herein, we discuss the past and current research relevant to targeting various CDKs in mucosal, uveal and acral melanomas. We also briefly describe the issue of amelanotic and desmoplastic types of melanoma and the need to do more research to discover cell cycle dysregulations, which cause the growth of the mentioned forms of cancer.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] CANCER THERAPY BY CYCLIN-DEPENDENT KINASE INHIBITORS (CDKIS): BENCH TO BEDSIDE
    Hassanzadeh, Ali
    Shomali, Navid
    Soltani-Zangbar, Mohammad Sadegh
    Nasiri, Hadi
    Akbari, Morteza
    EXCLI JOURNAL, 2024, 23 : 862 - 882
  • [22] Selectivity and potency of cyclin-dependent kinase inhibitors
    Sridhar, J
    Akula, N
    Pattabiraman, N
    AAPS JOURNAL, 2006, 8 (01): : E204 - E221
  • [23] Selectivity and potency of cyclin-dependent kinase inhibitors
    Jayalakshmi Sridhar
    Nagaraju Akula
    Nagarajan Pattabiraman
    The AAPS Journal, 8
  • [24] Cyclin-dependent kinase inhibitors in malignant hematopoiesis
    Schirripa, Alessia
    Sexl, Veronika
    Kollmann, Karoline
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [25] Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics
    Law, Mary E.
    Corsino, Patrick E.
    Narayan, Satya
    Law, Brian K.
    MOLECULAR PHARMACOLOGY, 2015, 88 (05) : 846 - 852
  • [26] Cyclin-dependent kinase inhibitors: The age of crystals
    Pines, J
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1997, 1332 (01): : M39 - M42
  • [27] Cyclin-dependent kinase inhibitors and human cancer
    Kamb, A
    CYCLIN DEPENDENT KINASE (CDK) INHIBITORS, 1998, 227 : 139 - 148
  • [28] Combination of Cyclin-Dependent Kinase 4 Inhibitors and Androgen Receptor Inhibitors as Cancer Therapy
    Abdel-Magid, Ahmed F.
    ACS MEDICINAL CHEMISTRY LETTERS, 2022, 13 (09): : 1408 - 1410
  • [29] Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of mucosal melanoma
    Chaoji Shi
    Houyu Ju
    Yunteng Wu
    Xuhui Ma
    Zhiyuan Zhang
    Guoxin Ren
    Holistic Integrative Oncology, 3 (1):
  • [30] Cyclins, cyclin-dependent kinases, cyclin-dependent kinase inhibitors and their role in head and neck cancer
    Jeannon, JP
    Wilson, JA
    CLINICAL OTOLARYNGOLOGY, 1998, 23 (05): : 420 - 424